OMB Approval
OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response: 14.90
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
BIOPHARMACEUTICS, INC.
---------------------------------------------------
Name of Issuer
COMMON STOCK
---------------------------------------------------
Title of Class of Securities
090646-10-0
---------------------------------------------------
CUSIP No.
JOHN FIGLIOLINI
201 E. 80th Street, Apartment 10-F
New York, New York 10021
212-794-1877
----------------------------------------------------
Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications
September 30, 1998
----------------------------------------------------
Date of Event Which Requires Filing of this Statement
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4),
check the following box: ______
<PAGE>
SCHEDULE 13D/A
CUSIP No. 090646-10-0
Page 2 of 3 Pages
1. Name of Reporting Person
JOHN P. FIGLIOLINI
2. Check the appropriate box if a member of a Group:
(A)
(B) X
3. SEC USE ONLY
4. SOURCE OF FUNDS
WC/PF/AF
5. Check box if disclosure of legal proceedings is required
pursuant to items 2(d) or 2 (e):
Not applicable.
6. Citizenship or place of organization:
USA
7. Sole Voting Power:
Yes - 974,341 Shares
8. Shared Voting Power:
No
9. Sole Dispositive Power:
Yes - 974,341 Shares
10. Shared Dispositive Power:
No
11. Aggregate Amount Beneficially owned by Each Reporting Person
974,341
<PAGE>
Page 3 of 3 Pages
12. Check box if the aggregate amount in row (11) excludes
certain shares:
Not applicable.
13. Percent of Class represented by amount in Row (11).
5.6%
14. Type of Reporting Person
EP/CO/IN/OO
ITEM 1. SECURITY AND ISSUER
This statement relates to the common stock, $.001 of Biopharmaceutics, Inc.,
a Delaware Corporation (the "Company"). The Company's principal executive
offices are located at 990 Station Road, Bellport, New York.
ITEM 2. IDENTITY AND BACKGROUND
16,000 Shares - Berkshire International Finance, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Berkshire is an Investment Banking firm owned by 100% by John P. Figliolini.
275,000 - Phillip Louis Trading, Inc.(formerly European Equity Partners, Inc.)
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Phillip Louis Trading, Inc. is a registered broker/dealer owned 100% by
John P. Figliolini.
26,116 Shares - Medical Technologies, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Medical Technologies, Inc. is a holding Company owned 100% by John P.
Figliolini.
25,000 Shares - Histon Financial Services, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Histon Financial Services, Inc. is owned 100% by John P. Figliolini.
57,725 Shares - Berkshire International Finance, Inc.
Pension and Profit Sharing Account
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
187,500 Shares - John P. Figliolini
201 E. 80th Street, Apt. 10-F
New York, New York 10021
365,000 Shares - Sierra Growth & Opportunity, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Sierra is owned 100% by John P. Figliolini.
22,000 Shares - Utopia Capital, Inc.
280 Route 35 South Suite 220
Red Bank, New Jersey 07701
Utopia Capital, Inc. is owned 100% by John P. Figliolini.
Mr. Figliolini is a registered rep and investment banker. During the last
five years, the Reporting Individual has not been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors) nor been
a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction resulting in him being subject to a judgment, decree
or final order enjoining future violations of, or prohibiting or mandating
activities subject to federal or state securities laws or finding any
violations with respect to such laws. The Reporting Individual is a
United States citizen.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
The source of funds used in making purchases of 146,841 shares was from
working capital and personal funds. No monetary compensation was paid to the
Company by the Reporting Individual for 827,000 shares. These shares were
issued to the Reporting Individual by the Company as compensation to the
Reporting Individual for finder fees and financing fees performed for the
Company.
ITEM 4. PURPOSE OF TRANSACTION
The purpose of the acquisition of the common stock is to make a speculative
investment and in order to provide consulting services and financing services
to the Company relating to past acquisition and financings and future
acquisitions and financing.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
According to information supplied to the Reporting Individual by the Company,
the number of shares of common stock outstanding as of June 30, 1998
is 17,264,143. Accordingly, the Reporting Individual is the beneficial owner
of 974,341 shares which is 5.6% of the outstanding common stock calculated
in accordance with Rule 13-D-3(d)(i). The Reporting Individual will have
sole voting and dispositive power with respect to these shares.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS
WITH RESPECT
TO SECURITIES OF THE ISSUER.
Other than the purchase of these shares, there are no other contracts,
arrangements, understandings or relationships (legal or otherwise) between
the Reporting Individual and any other person with respect to any securities
of the Company, including but not limited to, transfer or voting of any of
the securities of the Company, finder's fees, joint ventures, loan or option
arrangements, puts or calls guarantee of profits, division of profits and loss,
or the withholding of proxies.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
None.
Dated: November 2, 1998 /S/ JOHN P. FIGLIOLINI
------------------------
